Published on: Feb 1, 2017 | by finfeed Cellmid (ASX:CDY) announced on Tuesday that the US Patent and Trademark Office had issued Notice of Allowance for the patent application number 14/464,358 entitled "Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth" (midkine or MK alopecia patent). This development was well received by investors with the company's shares rallying more than 7% in the first half hour of trading and maintaining that level well into the afternoon. The midkine (MK) alopecia patent will expire in February 2031 and it adds to the significant intellectual property rights of Advangen Limited, Cellmid's wholly owned subsidiary engaged in the commercialisation of hair loss technologies. Other Advangen patents relate to the evolis® products that act through the inhibition of the FGF5 protein to prevent hair loss and increase hair growth. As a backdrop, Cellmid is an Australian life sciences company with prominent prog